LC
FOLD

Lindbrook Capital’s Amicus Therapeutics FOLD Stock Holding History

Lindbrook Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-223
Closed -$2.1K – 2838
2024
Q4 		$2.1K Buy
223
+163
+272% +$1.69K ﹤0.01% 2289
2024
Q3 		$641 Buy
+60
New +$653 ﹤0.01% 2603
2024
Q2 		– Sell
-40
Closed -$471 – 2787
2024
Q1 		$471 Sell
40
-101
-72% -$1.29K ﹤0.01% 2525
2023
Q4 		$2K Buy
141
+26
+23% +$295 ﹤0.01% 2261
2023
Q3 		$1.4K Sell
115
-231
-67% -$2.98K ﹤0.01% 2248
2023
Q2 		$4.35K Buy
346
+77
+29% +$914 ﹤0.01% 1875
2023
Q1 		$2.98K Sell
269
-75
-22% -$924 ﹤0.01% 2080
2022
Q4 		$4.2K Sell
344
-117
-25% -$1.32K ﹤0.01% 1909
2022
Q3 		$5K Buy
461
+339
+278% +$3.78K ﹤0.01% 1664
2022
Q2 		$1K Buy
122
+42
+53% +$346 ﹤0.01% 2232
2022
Q1 		$1K Buy
+80
New +$750 ﹤0.01% 2230

Other funds holding FOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Lindbrook Capital's FOLD Position: Q1 2025 in Review

Lindbrook Capital sold out of Amicus Therapeutics (FOLD) in Q1 2025, closing a stake of 223 shares — an estimated $2.1K sold.

Lindbrook Capital first reported a position in FOLD in Q1 2022 and held it in 11 quarters. The position peaked at $5K in Q3 2022. 286 funds tracked by Wall St. Rank hold FOLD as of Q1 2025.

  • Lindbrook Capital reported no remaining Amicus Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Lindbrook Capital sold 223 Amicus Therapeutics shares in Q1 2025, an estimated $2.1K.
  • Lindbrook Capital first reported a position in Amicus Therapeutics in Q1 2022 and held it in 11 quarters.
  • Lindbrook Capital's Amicus Therapeutics position peaked at $5K in Q3 2022.
  • 286 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.